Zacks Research Analysts Increase Earnings Estimates for Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Stock analysts at Zacks Research upped their Q3 2025 earnings per share estimates for Halozyme Therapeutics in a report issued on Monday, April 22nd. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will earn $1.01 per share for the quarter, up from their previous estimate of $0.98. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.45 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ FY2025 earnings at $3.92 EPS and Q1 2026 earnings at $1.21 EPS.

Several other equities analysts have also weighed in on HALO. StockNews.com raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, February 23rd. JMP Securities reissued a “market outperform” rating and set a $72.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, February 21st. Morgan Stanley cut their price target on Halozyme Therapeutics from $61.00 to $59.00 and set an “overweight” rating for the company in a report on Tuesday, December 26th. Benchmark reaffirmed a “buy” rating and issued a $50.00 price target on shares of Halozyme Therapeutics in a report on Tuesday, April 16th. Finally, TheStreet lowered Halozyme Therapeutics from a “b-” rating to a “c+” rating in a report on Monday, January 22nd. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $53.29.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $38.97 on Tuesday. The stock has a fifty day simple moving average of $39.62 and a two-hundred day simple moving average of $37.78. Halozyme Therapeutics has a 1-year low of $29.85 and a 1-year high of $45.00. The firm has a market cap of $4.95 billion, a price-to-earnings ratio of 18.48, a price-to-earnings-growth ratio of 0.45 and a beta of 1.25. The company has a current ratio of 6.64, a quick ratio of 5.50 and a debt-to-equity ratio of 17.89.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the consensus estimate of $0.77 by ($0.02). Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. The firm had revenue of $230.04 million for the quarter, compared to the consensus estimate of $235.25 million.

Insider Activity at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $41.64, for a total transaction of $416,400.00. Following the completion of the sale, the senior vice president now owns 156,558 shares of the company’s stock, valued at $6,519,075.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders sold 30,000 shares of company stock valued at $1,196,800. Company insiders own 2.70% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

Several large investors have recently added to or reduced their stakes in HALO. Rise Advisors LLC bought a new stake in Halozyme Therapeutics during the first quarter valued at $25,000. Principal Securities Inc. purchased a new stake in Halozyme Therapeutics during the fourth quarter valued at about $34,000. First Horizon Advisors Inc. raised its position in Halozyme Therapeutics by 24.5% during the fourth quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 293 shares in the last quarter. Parkside Financial Bank & Trust purchased a new stake in Halozyme Therapeutics during the fourth quarter valued at about $64,000. Finally, Headlands Technologies LLC raised its position in Halozyme Therapeutics by 1,068.2% during the fourth quarter. Headlands Technologies LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 1,613 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.